Two key patent cases that no doubt will impact the future of personalized medicine are pending review by the US Supreme Court. What will the Court decide?
Covering the life sciences inside and out
Two key patent cases that no doubt will impact the future of personalized medicine are pending review by the US Supreme Court. What will the Court decide?
Pharmaceutical companies should deploy cash to fund struggling biotech companies, which could generate much needed new drugs.
After 10 years in development, a novel mouse population proves its mettle in complex trait research.
Funding only outstanding researchers is increasing the gap between good and great labs and forcing some out of science in search of a bigger paycheck.
Designing the simplest possible living organism artificially may lend clues as to what life is.
While biotechnology has met with mixed public reactions, to date nanotechnology seems to invoke much less public concern.
Celebrity spokespeople for pharma companies can manipulate the public’s understanding of disease.
Research in yeast shows that aneuploidy is both a consequence of and an adaptation to stress.
Biomedical research can learn from citizen science, which is grounded in strong relationships with study participants.